Literature DB >> 21147285

Changing patterns of ST elevation myocardial infarction epidemiology.

Leonardo Bolognese1.   

Abstract

Despite advances in both the early management and longer-term treatment of acute myocardial infarction, this condition still represents a leading cause of morbidity and mortality in western countries, making essential understanding its determinants. All epidemiologic studies examining prognosis after acute myocardial infarction have used data collected in the midst of the epidemic, possibly giving rise to conflicting results. Hospitalization rates for myocardial infarction have remained relatively stable for the past five decades, in the face of declining coronary heart disease risk factor prevalence and mortality rates, yielding to a paradoxical effect. Many factors like the decrease in severity of such disease and the changes in myocardial infarction definitions may have contributed to such phenomenon. Moreover, because non-ST elevation myocardial infarctions now constitute most of cases in communities, interventions must be designed that recognize this epidemiological reality. At the same time, improved survival in recent decades may have contributed to an increase in the pool of people at risk for developing HF. Thus, the epidemiology and treatment of this condition has not stood still.
Copyright © 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21147285     DOI: 10.1016/j.ahj.2010.10.008

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

1.  Association between PON1 rs662 polymorphism and coronary artery disease.

Authors:  T Liu; X Zhang; J Zhang; Z Liang; W Cai; M Huang; C Yan; Z Zhu; Y Han
Journal:  Eur J Clin Nutr       Date:  2014-06-11       Impact factor: 4.016

Review 2.  Calpains, mitochondria, and apoptosis.

Authors:  Matthew A Smith; Rick G Schnellmann
Journal:  Cardiovasc Res       Date:  2012-05-11       Impact factor: 10.787

3.  The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: A case-match study.

Authors:  Younes Nozari; Sirous Vosooghi; Mohammadali Boroumand; Hamidreza Poorhosseini; Ebrahim Nematipour; Mojtaba Salarifar; Seyed Ebrahim Kassaian; Alireza Amirzadegan; Mohammad Alidoosti; Ali Mohammad Haji-Zeinali; Sepideh Saroukhani
Journal:  Anatol J Cardiol       Date:  2015-05       Impact factor: 1.596

4.  Serum YKL-40 positively correlates with MMP-9 and CRP in patients with acute ST segment elevation myocardial infarction following emergency treatment.

Authors:  Yuanfei Tan; Xiaoying Ji; Zhifeng Mo; Yaoliang Zhou
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

5.  SCD leads to the development and progression of acute myocardial infarction through the AMPK signaling pathway.

Authors:  Lijie Wang; Fengxia Yu
Journal:  BMC Cardiovasc Disord       Date:  2021-04-20       Impact factor: 2.298

6.  Cytochrome P450 2C19 Polymorphism in Iranian Patients with Coronary Artery Disease.

Authors:  Arash Akhlaghi; Shahin Shirani; Naghmeh Ziaie; Omid Pirhaji; Majid Yaran; Golnoosh Shahverdi; Nizal Sarrafzadegan; Alireza Khosravi; Elham Khosravi
Journal:  ARYA Atheroscler       Date:  2011

7.  Immediate results and six-month outcomes after percutaneous coronary intervention in a referral heart center in Isfahan, Iran.

Authors:  Alireza Khosravi; Masoud Pourmoghaddas; Kourosh Asadi; Ahmadnoor Abdi; Ali Gholamrezaei
Journal:  ARYA Atheroscler       Date:  2011

8.  Serum VEGF Predicts Worse Clinical Outcome of Patients with Coronary Heart Disease After Percutaneous Coronary Intervention Therapy.

Authors:  Xia Han; Lili Liu; Jiamin Niu; Jun Yang; Zengtang Zhang; Zhiqiang Zhang
Journal:  Med Sci Monit       Date:  2015-10-26

9.  Common rs5918 (PlA1/A2) polymorphism in the ITGB3 gene and risk of coronary artery disease.

Authors:  Mehri Khatami; Mohammad Mehdi Heidari; Sorour Soheilyfar
Journal:  Arch Med Sci Atheroscler Dis       Date:  2016-04-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.